ArticleLangenbeck's archives of surgery2026
Prognostic impact of pathologically confirmed venous infiltration during upfront pancreatectomy: multicenter survival analysis.
Article in Langenbeck's archives of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePancreatectomy with venous resection (PVR) for resectable pancreatic ductal adenocarcinoma (PDAC) may be preoperatively planned or intraoperatively required due to suspected vascular involvement. The prognostic impact of pathologically confirmed venous infiltration (PVI) in upfront PVR remains unclear. This study assesses such impact on overall survival (OS).
methodsPatients who underwent upfront PVR for PDAC were identified from a prospectively maintained database across three high-volume institutions. Clinical and pathological variables, including PVI status, were collected. Survival outcomes and predictors were analyzed using Cox regression models.
resultsA total of 295 patients underwent upfront PVR. Segmental end-to-end reconstruction (Type III) was the most common approach (69%). PVI was confirmed in 66% of cases. Adjuvant therapy was administered to 69% of patients. Median OS was 32 months for PVI-negative vs. 21.1 months for PVI-positive patients (HR 1.49, 95% CI: 1.02–2.17, p = 0.037). One- and three-year survival rates were significantly lower in the PVI-positive group. Among PVI-positive patients, OS was 7 months without adjuvant therapy and 29.5 months with, aligning with outcomes in PVI-negative patients who received adjuvant treatment (HR 1.51, p = 0.104). Independent predictors of OS included PVI (HR 1.67), age ≥ 75 (HR 1.93), N2 status (HR 1.89), total pancreatectomy (HR 2.42) and adjuvant therapy (HR 0.33).
conclusionsMore than one-third of patients undergoing upfront PVR for suspected venous infiltration are overtreated as they lack pathologically confirmed vessel involvement. Conversely, when PVI is present, survival is significantly impaired. The successful delivery of adjuvant chemotherapy in case of PVI ameliorates outcomes as in cases lacking venous involvement.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.